Comparison of Homology Medicines Inc. (FIXX) and InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV)

Homology Medicines Inc. (NASDAQ:FIXX) and InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Homology Medicines Inc. 3.68M 268.63 57.22M -2.50 0.00
InVivo Therapeutics Holdings Corp. N/A 0.00 25.56M -94.77 0.00

Table 1 shows the gross revenue, earnings per share and valuation for Homology Medicines Inc. and InVivo Therapeutics Holdings Corp.


Table 2 demonstrates the return on equity, net margins and return on assets of Homology Medicines Inc. and InVivo Therapeutics Holdings Corp.

Net Margins Return on Equity Return on Assets
Homology Medicines Inc. -1,554.89% 0% 0%
InVivo Therapeutics Holdings Corp. 0.00% -292.1% -140.7%


The Current Ratio of Homology Medicines Inc. is 13.2 while its Quick Ratio stands at 13.2. The Current Ratio of rival InVivo Therapeutics Holdings Corp. is 6.9 and its Quick Ratio is has 6.9. Homology Medicines Inc. is better equipped to clear short and long-term obligations than InVivo Therapeutics Holdings Corp.

Analyst Recommendations

In next table is shown Homology Medicines Inc. and InVivo Therapeutics Holdings Corp.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Homology Medicines Inc. 0 0 1 3.00
InVivo Therapeutics Holdings Corp. 0 0 0 0.00

Homology Medicines Inc. has a 35.90% upside potential and a consensus price target of $36.

Institutional and Insider Ownership

Roughly 91.6% of Homology Medicines Inc. shares are held by institutional investors while 13.2% of InVivo Therapeutics Holdings Corp. are owned by institutional investors. Insiders held roughly 10.06% of Homology Medicines Inc.’s shares. Insiders Comparatively, held 0.1% of InVivo Therapeutics Holdings Corp. shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Homology Medicines Inc. 6.25% 41.64% 30.09% 80.11% 0% 28.4%
InVivo Therapeutics Holdings Corp. 2.59% -13.1% -26.87% -23.46% -87.15% -2.17%

For the past year Homology Medicines Inc. has 28.4% stronger performance while InVivo Therapeutics Holdings Corp. has -2.17% weaker performance.


On 8 of the 10 factors Homology Medicines Inc. beats InVivo Therapeutics Holdings Corp.

Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, via a single intravenous injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle and eye, across modalities?gene editing and gene therapy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, focus on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for acute SCI; and Therapeutic Trails injection program for the treatment of chronic SCI. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.